Bruno Baptista

Dr. Bruno Baptista

University of Beira Interior, Covilhã, Castelo Branco, Portugal
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
BBBruno Baptista
Bruno Baptista
MRM. Riscado
M. Riscado
JQJ.A. Queiroz
J.A. Queiroz
CPC. Pichon
C. Pichon
Fani SousaFani Sousa
Fani Sousa

5 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
BBBruno Baptista
Bruno Baptista
RCRita Mugeiro Carapito
Rita Mugeiro Carapito
NLNabila LAROUI
Nabila LAROUI
Chantal PichonChantal Pichon
Chantal Pichon
Fani SousaFani Sousa
Fani Sousa
The perspective of using messenger RNA (mRNA) as a therapeutic molecule first faced some uncertainties due to concerns about its instability and the feasibility of large-scale production. Today, given technological advances and deeper biomolecular knowledge, these issues have started to be addressed and some strategies are being exploited to overcome the limitations. Thus, the potential of mRNA has become increasingly recognized for the development of new innovative therapeutics, envisioning its application in immunotherapy, regenerative medicine, vaccination, and gene editing. Nonetheless, to fully potentiate mRNA therapeutic application, its efficient production, stabilization and delivery into the target cells are required. In recent years, intensive research has been carried out in this field in order to bring new and effective solutions towards the stabilization and delivery of mRNA. Presently, the therapeutic potential of mRNA is undoubtedly recognized, which was greatly reinforced by the results achieved in the battle against the COVID-19 pandemic, but there are still some issues that need to be improved, which are critically discussed in this review.

3 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MRMicaela Riscado
Micaela Riscado
BBBruno Baptista
Bruno Baptista
Fani SousaFani Sousa
Fani Sousa
Dementia is described as the fifth leading cause of death worldwide and Alzheimer’s disease (AD) is recognized as the most common, causing a huge impact on health costs and quality of patients’ lives. The main hallmarks that are commonly associated with the pathologic process are amyloid deposition, pathologic Tau phosphorylation and neurodegeneration. It is still unclear how these events are linked to the disease progression, due to the complex pathologic mechanisms. Nevertheless, several hypotheses have been proposed for a better understanding of AD. The AD diagnosis is performed by using a combination of several tools to detect β-amyloid peptide (Aβ) deposits and modifications in cognitive performance, sometimes being expensive and invasive. In the treatment field, there is still an absence of effective treatments to delay or stop the progression of the disease, with most of the approved drugs used to relieve symptoms, and all of them with significant adverse side effects. Considering all limitations, the need to establish new and more effective diagnostic and therapeutic strategies becomes clear. This review aims not only to describe the disease and its impact but also to collect the currently available diagnostic and therapeutic strategies, highlighting new promising RNA-based strategies for AD.

23 December 2022 in Materials Science and Engineering: C
Verified
Journal Article
Open access
BBBruno Baptista
Bruno Baptista
AOAndreia S.R. Oliveira
Andreia S.R. Oliveira
PMPatrícia Mendonça
Patrícia Mendonça
ASArménio C. Serra
Arménio C. Serra
JCJorge F.J. Coelho
Jorge F.J. Coelho
Fani SousaFani Sousa
Fani Sousa
The use of gene-based products, such as DNA or RNA, is increasingly being explored for various innovative therapies. However, the success of these strategies is highly dependent on the effective delivery of these biomolecules to target cells. Therefore, the development of pH-responsive nanoparticles comprises the creation of intelligent delivery systems with high therapeutic efficiency. In this work, the pH-responsiveness of the poly(2-(diisopropylamino)ethyl methacrylate)) (PDPA) block was investigated for the encapsulation and delivery of small RNAs (sRNA) to cancer cells. The pH responsiveness was dependent on the protonation profile of the tertiary amines of PDPA, which directly affected the electrostatic interactions established with RNA. Thus, block copolymers based on poly(oligo(ethylene oxide) methyl ether methacrylate) (POEOMA) and PDPA, POEOMA-b-PDPA, were synthesized by supplemental activator and reducing agent atom transfer radical polymerization (SARA ATRP). The structure of the block copolymers was characterized by size exclusion chromatography and 1H NMR spectroscopy. The copolymers allowed effective complexation of model sRNAs and a pre-miRNA with efficiencies of about 89 % and 91 %, respectively. The characterization by dynamic light scattering revealed that these systems had sizes between 76 and 1375 nm. It was also found that the morphology of the polyplexes depended on the pH, since the preparation at a pH lower than the pKa of the copolymers resulted in spherical but polydisperse particles, while higher pH values resulted in nanoparticles with more homogeneous size, but altered morphology. Moreover, due to pH-responsiveness, it was achieved the release of RNA at pH higher than the pKa of the copolymers, while maintaining its integrity. The polyplexes also showed a high potential to protect RNA from RNases. The transfection of a lung cancer model (A549) and fibroblast cell lines showed that these polyplexes did not cause cell toxicity. In addition, the polyplexes enabled the effective transfection of the A549 cell line with pre-miRNA-29b and miRNA-29b, resulting in a decrease of expression levels of the target DNMT3B gene by approximately 51 % and 47 %, respectively. Overall, the POEOMA-b-PDPA copolymers proved to be a promising strategy for developing responsive delivery systems, that can play a critical role in some diseases, such as cancer, where pH varies between the intra and extracellular environments.

22 January 2025 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Open access
AMAndré Miranda
André Miranda
BBBruno Baptista
Bruno Baptista
MFMarília Figueira
Marília Figueira
Fani SousaFani Sousa
Fani Sousa
Cláudio MaiaCláudio Maia
Cláudio Maia
Carla CruzCarla Cruz
Carla Cruz
Rapid, quantitative, and sensitive detection of viral oligonucleotides can help to diagnose the infection before symptoms occur, monitor disease progression, and identify viral subtypes. A one-pot, simple, rapid hairpin-mediated nicking enzymatic signal amplification (HNESA) method was previously developed for nucleic acids detection. In the present work, this method was applied for the detection of SARS-CoV-2 RNA by designing an assistant probe (AP) that contains the complementary sequence for the target, the sequence of hybridization with the loop region of the molecular beacon (MB), and the recognition site of the nicking endonuclease Nt.BstNBI. MB sequences (MB1 and MB2) were also designed and optimized in length and nucleotide composition. MB2 significantly amplified the fluorescence signal of the target sequence. The linear range was from 0.1 to 1 nM with a detection limit of 170.6 pM. Results can be obtained within 45 min, considering that the cyclic amplification involves only one AP and one MB. Based on this, the use of HNESA for diagnosing viral diseases, such as SARS-CoV-2, could be a complementary approach to polymerase chain reaction (PCR), and it is a technique that is quick, efficient and has high sensitivity.